Regenocell Therapeutics Inc Natick, MA - 01760

Regenocell Therapeutics Inc is categorized under Diagnostic Substances in Natick, MA and active since 2008.

Regenocell Therapeutics Inc was established in 2008, and today employs 1 to 4, earning $500.000 to $999.999 per year. This is a Diagnostic Substances business, which does work in the B2B market, and is classified as a Diagnostic Substances, under code number 325412 by the NAICS.

If you are seeking more information, feel free to contact James Mongiardo at the company’s single location by writing to 58 North Main St Apartment 201, Natick, Massachusetts MA 01760 or by phoning (407) 415-6359. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.

Business Name: Regenocell Therapeutics Inc
Contact Person: James Mongiardo
Address: 58 North Main St Apartment 201, Natick, Massachusetts 01760
Phone Number: (407) 415-6359
Annual Revenue (USD): $500.000 to $999.999
Founded: 2008
Location Type: Single Location
Employee Number: 1 to 4
Business Type: B2B (Business to Business)
Business Category: Diagnostic Substances
SIC Code: 2835
NAICS Code: 325412
Share This Business:

Regenocell Therapeutics Inc was started in 2008 to provide professional Diagnostic Substances under the SIC code 2835 and NAICS code 325412. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $500.000 to $999.999 per annum.

Feel free to contact James Mongiardo for inquiries that concern Regenocell Therapeutics Inc by calling the company number (407) 415-6359, as your correspondence is most welcome. Additionally, the physical location of the single location of Regenocell Therapeutics Inc can be found at the coordinates 42.288885,-71.350842 as well as the street address 58 North Main St Apartment 201 in Natick, Massachusetts 01760.

For its online presence, you may visit Regenocell Therapeutics Inc’s website at and engage with its social media outlets through on Twitter and on Facebook.